Fibrosis-related events play a part in the pathogenesis or failure of treatment of virtually all the blinding diseases around the world, and also account for over 40% of all deaths. It is well established that the eye and other tissues of some group of patients, for example Afro-Caribbean people, scar worse than others. However, there is a current lack of reliable biomarkers to stratify the risk of scarring and postsurgical fibrosis in the eye.
This report contains market size and forecasts of Anti-Fibrotic Therapy for Ocular Fibrosis in global, including the following market information:
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Anti-Fibrotic Therapy for Ocular Fibrosis companies in 2021 (%)
The global Anti-Fibrotic Therapy for Ocular Fibrosis market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anti-Fibrotic Therapy for Ocular Fibrosis include Roche, Novatis, Bayer, Baxter, Hikma, Cipla, GSK, Aspen Pharmacare and Mylan Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-Fibrotic Therapy for Ocular Fibrosis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Segment Percentages, by Type, 2021 (%)
Injection
Oral
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Segment Percentages, by Application, 2021 (%)
Hospital
Eye Clinic
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-Fibrotic Therapy for Ocular Fibrosis revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Anti-Fibrotic Therapy for Ocular Fibrosis revenues share in global market, 2021 (%)
Key companies Anti-Fibrotic Therapy for Ocular Fibrosis sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Anti-Fibrotic Therapy for Ocular Fibrosis sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novatis
Bayer
Baxter
Hikma
Cipla
GSK
Aspen Pharmacare
Mylan Pharmaceuticals
Sun Pharmaceutical